RT Journal Article SR Electronic T1 Uncovering Survivorship Bias in Longitudinal Mental Health Surveys During the COVID-19 Pandemic JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.28.21250694 DO 10.1101/2021.01.28.21250694 A1 M. Czeisler A1 J. Wiley A1 C. Czeisler A1 S. Rajaratnam A1 M. Howard YR 2021 UL http://medrxiv.org/content/early/2021/04/06/2021.01.28.21250694.abstract AB Aims Markedly elevated adverse mental health symptoms were widely observed early in the coronavirus disease 2019 (COVID-19) pandemic. Unlike the U.S., where cross-sectional data indicate anxiety and depression symptoms have remained elevated, such symptoms reportedly declined in the U.K., according to analysis of repeated measures from a largescale longitudinal study. However, nearly 40% of U.K. respondents (those who did not complete multiple follow-up surveys) were excluded from analysis, suggesting that survivorship bias might partially explain this discrepancy. We therefore sought to assess survivorship bias among participants in our longitudinal survey study as part of The COVID-19 Outbreak Public Evaluation (COPE) Initiative.Methods Survivorship bias was assessed 4,039 U.S. respondents who completed surveys including the assessment of mental health as part of The COPE Initiative in April 2020 and were invited to complete follow-up surveys. Participants completed validated screening instruments for symptoms of anxiety, depression, and insomnia. Survivorship bias was assessed for (1) demographic differences in follow-up survey participation, (2) differences in initial adverse mental health symptom prevalences adjusted for demographic factors, and (3) differences in follow-up survey participation based on mental health experiences adjusted for demographic factors.Results Adjusting for demographics, individuals who completed only one or two out of four surveys had higher prevalences of anxiety and depression symptoms in April 2020 (e.g., one-survey versus four-survey, anxiety symptoms, adjusted prevalence ratio [aPR]: 1.30, 95% confidence interval [CI]: 1.08-1.55, P=0.0045; depression symptoms, aPR: 1.43, 95% CI: 1.17-1.75, P=0.00052). Moreover, individuals who experienced incident anxiety or depression symptoms had higher odds of not completing follow-up surveys (adjusted odds ratio [aOR]: 1.68, 95% CI: 1.22-2.31, P=0.0015, aOR: 1.56, 95% CI: 1.15-2.12, P=0.0046, respectively).Conclusions Our findings revealed significant survivorship bias among longitudinal survey respondents, indicating that restricting analytic samples to only respondents who provide repeated assessments in longitudinal survey studies could lead to overly optimistic interpretations of mental health trends over time. Cross-sectional or planned missing data designs may provide more accurate estimates of population-level adverse mental health symptom prevalences than longitudinal surveys.Competing Interest StatementAll authors report institutional grants to Monash University from the CDC Foundation, with funding from BNY Mellon, and from WHOOP, Inc. MC reported grants from the Fulbright Foundation sponsored by The Kinghorn Foundation and personal fees from Vanda Pharmaceuticals Inc. CC reported receiving personal fees from Teva Pharma Australia, Inselspital Bern, the Institute of Digital Media and Child Development, the Klarman Family Foundation, Tencent Holdings Ltd, the Sleep Research Society Foundation, and Physician's Seal. CC reports receiving grants to Brigham and Women's Hospital from the Federal Aviation Administration, the National Health Lung and Blood Institute, the National Institute on Aging, the National Aeronautics and Space Administration, and the National Institute of Occupational Safety and Health R01-OH-011773. CC reports receiving personal fees from and equity interest in Vanda Pharmaceuticals Inc., educational and research support from Jazz Pharmaceuticals Plc, Philips Respironics Inc., Regeneron Pharmaceuticals, and Sanofi S.A. CC reports an endowed professorship provided to Harvard Medical School from Cephalon, Inc., an institutional gift from Alexandra Drane, and a patent on Actiwatch-2 and Actiwatch-Spectrum devices, with royalties paid from Philips Respironics, Inc. CC's interests were reviewed and managed by Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict of interest policies. CC also served as a voluntary board member for the Institute for Experimental Psychiatry Research Foundation and a voluntary consensus panel chair for the National Sleep Foundation. SR reported receiving grants and personal fees from Cooperative Research Centre for Alertness, Safety and Productivity, receiving grants and institutional consultancy fees from Teva Pharma Australia, and institutional consultancy fees from Vanda Pharmaceuticals, Circadian Therapeutics, BHP Billiton, and Herbert Smith Freehills. No other disclosures were reported.Funding StatementThe present work was supported by institutional grants to Monash University from CDC Foundation with funding from BNY Mellon and from WHOOP, Inc., and by institutional support from Philips Respironics and Alexandra Drane to Brigham & Women's Hospital, the Turner Institute for Brain and Mental Health, Monash University, and the Institute for Breathing and Sleep, Austin Hospital. M.C. gratefully acknowledges support from a 2020-2021 Fulbright Fellowship sponsored by The Kinghorn Foundation. This manuscript reflects the views of the authors and does not necessarily represent the official position of the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Monash University Human Research Ethics Committee approved the study (#24036). Participants provided electronic informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data supporting the findings in this study are available from the corresponding author upon reasonable request.